Cagrilintide is a long-acting amylin analog studied for chronic weight management, both on its own and paired with semaglutide in the combination Novo Nordisk advanced through the REDEFINE Phase 3 program. Unlike a stimulant, it does not produce a same-day effect — the published trials titrated the dose upward over weeks and measured their primary weight endpoints at 26 weeks (Phase 2) and 68 weeks (Phase 3). The speed at which any individual sees change is shaped by the titration pace, baseline body weight, whether semaglutide is co-administered, and ordinary biological variation.
Research-context information only. Cagrilintide is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
This timeline is built from the trial record — primarily the Phase 2 monotherapy dose-finding study (Lau et al., 2021) and the REDEFINE Phase 3 combination trials (Aronne et al., 2025; Lingvay et al., 2025) — plus the Phase 1b pharmacodynamic data (Enebo et al., 2021). Every outcome figure below is attributed to its trial. The trials measured cohorts, not individuals; documented timelines describe averages, and individual response varied.
The timing of effects tracks the mechanism. Cagrilintide is an acylated analog of amylin, a hormone co-secreted with insulin after meals. It activates amylin receptors in the brainstem — the area postrema and nucleus of the solitary tract — which govern satiety, meal size, and gastric emptying (Lau et al., 2021).
Two features set the pace observed in trials:
Long half-life. Cagrilintide's fatty-acid acylation extends its half-life to roughly 160 hours, so circulating levels rise gradually over the first weeks of dosing rather than peaking immediately (Enebo et al., 2021).
Stepwise titration. The REDEFINE protocol escalated the dose over 16 weeks (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), so the full pharmacologic dose was not reached until roughly week 17. Appetite effects appeared earlier than the maximal weight loss because they began at sub-maintenance doses.
In short, trial data describe early appetite and satiety shifts, followed by progressively larger body-weight changes as the dose climbed and treatment continued.
Week 1: Early Pharmacodynamic Changes
What the trials documented:
The Phase 1b combination study measured reduced food intake and slowed gastric emptying among the earliest pharmacodynamic signals after dosing began, while the dose was still at the lowest titration step (Enebo et al., 2021).
Body weight had not meaningfully separated from placebo in the first week of any published trial. Trial curves show the weight-loss slope steepening over subsequent weeks, not in the first.
What community sources describe:
Self-reported community timelines describe earlier satiety and smaller portion sizes as the first noticeable change, often within the first one to two weeks.
Community reports cluster around mild, transient nausea appearing during the same early window — consistent with the gastrointestinal adverse-event pattern trials documented during titration (Lau et al., 2021).
Realistic expectation: The trial record frames week one as a priming phase. Appetite signals can begin, but measurable weight change in the first week was not a documented trial outcome.
Weeks 2-4: Appetite Effects Build, Early Weight Separation
What the trials documented:
Across the Phase 2 dose-finding trial, weight in the cagrilintide arms began separating from placebo during the initial weeks of titration, with the gap widening at every dose level as the study progressed (Lau et al., 2021).
Gastrointestinal adverse events — nausea most commonly — were most frequent during these dose-escalation weeks. In Phase 2, 41–63% of cagrilintide participants reported GI events versus 32% on placebo, with nausea the leading complaint; trial data describe these events as predominantly mild to moderate and tending to ease after titration (Lau et al., 2021).
What community sources describe:
Users in community sources commonly describe appetite suppression becoming more consistent across the day by weeks two to four, with the scale beginning to move modestly.
Realistic expectation: Trial data place the first measurable weight separation in this window, but the numbers were still early-stage. The dominant documented experience in these weeks was appetite change and titration-phase GI effects rather than large body-composition shifts.
Months 1-2: Weight Loss Accelerates
What the trials documented:
In the Phase 2 monotherapy trial, weight loss accrued steadily through the dosing period, building toward the 26-week endpoints of 9.1% at the 2.4 mg dose and 10.8% at 4.5 mg (Lau et al., 2021). The first two months represented the rising portion of that curve, not the peak.
The Phase 2 combination trial in type 2 diabetes reported that, by its 32-week endpoint, the cagrilintide-plus-semaglutide arm reached 15.6% mean weight loss versus 8.1% for cagrilintide alone and 5.1% for semaglutide alone — with the combination curve already diverging upward through the early months (Frias et al., 2023).
What community sources describe:
Self-reported community timelines describe months one to two as the period when weight change becomes clearly visible rather than just felt as reduced appetite.
Realistic expectation: The trial record frames this stage as the acceleration phase. For combination protocols, published curves show the cagrilintide-plus-semaglutide arm pulling ahead of either single agent during this period (Frias et al., 2023).
Months 3-6: Approaching the Maintenance Phase
What the trials documented:
By around month four (week 17), the REDEFINE protocol reached the 2.4 mg maintenance dose, and weight loss continued to accrue beyond that point through the 68-week primary endpoint (Aronne et al., 2025).
REDEFINE 1, in adults with overweight or obesity without diabetes, reported 22.7% mean weight loss for the combination at 68 weeks on the on-treatment analysis, with 60% of combination participants reaching at least 20% loss and 23% reaching at least 30% (Aronne et al., 2025). The trial's intention-to-treat estimate was a 20.4% mean reduction.
REDEFINE 2, in adults with overweight or obesity and type 2 diabetes, reported a 13.7% mean reduction at 68 weeks versus 3.4% on placebo (Lingvay et al., 2025).
The 26-week and 68-week figures make clear that months three to six captured only part of the total trajectory — the published curves were still descending at six months, with substantial additional loss recorded over the back half of the trials.
What community sources describe:
The most consistent community feedback is that the three-to-six-month window is where results feel established, though community cycles are typically far shorter than the 26–68-week trial durations and may not reach the same totals.
Realistic expectation: Trial data document the largest weight changes accruing over windows longer than six months. Anyone reading the 22.7% or 10.8% figures should note these were measured at 68 and 26 weeks respectively — not at three months (Aronne et al., 2025; Lau et al., 2021).
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
30ml from $18.75 · Ships fast · Code thepeptidecatalog
Factors That Affect Results
Several variables shaped the documented trajectories:
Factors associated with larger or faster documented effects:
Co-administration with semaglutide. Trial data consistently show the combination arms exceeding cagrilintide-alone arms — 15.6% vs 8.1% at 32 weeks in the Phase 2 diabetes trial (Frias et al., 2023), and a 22.7% combination figure at 68 weeks in REDEFINE 1 (Aronne et al., 2025).
Higher maintenance dose. Phase 2 documented a clear dose-response: 9.1% at 2.4 mg versus 10.8% at 4.5 mg at 26 weeks (Lau et al., 2021).
Treatment duration. The longest trial windows produced the largest reductions; the curves had not fully plateaued by their endpoints.
Factors associated with slower or smaller documented effects:
Type 2 diabetes status. REDEFINE 2 documented smaller mean weight loss (13.7%) in a diabetes population than REDEFINE 1 (22.7% on-treatment) in a population without diabetes — a pattern consistent across the incretin-therapy literature (Lingvay et al., 2025; Aronne et al., 2025).
Titration interruptions. Trial data describe titration as central to tolerability; the protocols paused or slowed escalation when GI events were significant, which extended the time to the maintenance dose.
What If the Timeline Shows Nothing
The trials measured group averages, and not every participant responded identically. The published protocols did not define an individual "non-responder" rescue plan, so the points below describe what community sources flag — not medical instructions.
Reconstitution and dose accuracy. Community sources describe re-checking the reconstitution math first — an error in dilution or draw volume changes the delivered dose. The cagrilintide dosing guide documents the mixing math.
Titration pace. Trial protocols reached the full pharmacologic dose only at roughly week 17; community reports note that a slow or interrupted titration delays the window in which larger effects appeared.
Time horizon. Because the headline trial figures were measured at 26 and 68 weeks, community sources caution against judging response on a few weeks of data when the trial curves were still descending well past month six (Lau et al., 2021; Aronne et al., 2025).
Monotherapy vs combination. Cagrilintide alone produced roughly half the weight loss of the cagrilintide-plus-semaglutide combination in head-to-head trial arms (Frias et al., 2023) — a documented difference, not a recommendation to combine.
Frequently Asked Questions
How quickly did cagrilintide produce weight loss in trials?
In the Phase 2 dose-finding trial, weight separated from placebo within the first few weeks of titration, but the largest reductions accrued over the full 26 weeks, reaching 10.8% mean weight loss at the 4.5 mg dose (Lau et al., 2021). The REDEFINE Phase 3 trials measured their primary endpoint at 68 weeks, so the headline combination figures reflect more than a year of continuous treatment.
What did trials report as the first sign cagrilintide was working?
Trial protocols describe reduced food intake and earlier satiety as the earliest pharmacodynamic effects of amylin receptor activation. The Phase 1b combination study documented appetite and gastric-emptying changes during the initial weeks of dosing, before meaningful body-weight separation (Enebo et al., 2021).
Why is cagrilintide titrated so slowly in trials?
The REDEFINE program used a 16-week step-up to the 2.4 mg maintenance dose. Trial data describe titration as central to gastrointestinal tolerability — most nausea, the most common adverse event, clustered during dose-escalation weeks and tended to ease afterward (Lau et al., 2021; Enebo et al., 2021).
How much weight loss did the combination trials document at the end?
REDEFINE 1 reported 22.7% mean weight loss for the cagrilintide-plus-semaglutide combination at 68 weeks on the on-treatment analysis (Aronne et al., 2025). REDEFINE 2, in adults with type 2 diabetes, reported a 13.7% mean reduction at 68 weeks (Lingvay et al., 2025).
What did trials report when results plateaued or stalled?
Published curves show weight loss continuing to accrue across the full trial windows, with the rate of loss slowing as participants approached the maintenance phase. The trials did not report a protocol for what an individual should do if no response occurred; community sources describe re-checking reconstitution math, injection consistency, and titration pacing as first steps to investigate.
Research Supplies for Cagrilintide
Hand-picked storage, injection, and recovery supplies paired with Cagrilintide protocols.
Lau, D. C. W., Erichsen, L., Francisco, A. M., et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet, 398(10317), 2160-2172. PubMed
Enebo, L. B., Berthelsen, K. K., Kankam, M., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. The Lancet, 397(10286), 1736-1748. PubMed
Frias, J. P., Deenadayalan, S., Erichsen, L., et al. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. The Lancet, 402(10403), 720-730. PubMed
Aronne, L. J., Horn, D. B., le Roux, C. W., et al. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). New England Journal of Medicine. PubMed
Lingvay, I., Mosenzon, O., Brown, K., et al. (2025). Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). New England Journal of Medicine. PubMed
For educational and research purposes only. This is not medical advice. Cagrilintide is investigational and not FDA-approved. All information is derived from published clinical research.
